Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Bionovo Announces Publication of Data on Potential Increase in Breast Cancer Risk Due to the Inhibitory Effect of Tamoxifen Treatment on Estrogen Receptor Beta
November 3rd, 2009
Bionovo Inc. (NASDAQ:BNVI) announced the publication of results from its study on the inhibitory effect of tamoxifen on estrogen receptor beta (ERb) gene regulation. The results of the study, which will be published in Molecular and Cellular Endocrinology, demonstrate that tamoxifen inhibits the beneficial effects of ERb in the prevention of breast cancer cell proliferation. "Tamoxifen has been successfully used to treat and prevent breast cancer. However, some breast tumors become resistant to its effects. So, it is critical to discover new estrogens that work through a different mechanism," stated Dr. Dale Leitman, the Principal Investigator of the study. "In this...
Source: Cancer Weekly (2009-11-03)
|
